- PDLI Ticker
- 🇺🇸 NASDAQ Exchange
- 87 Employees
- 💊 Health Care Sector
- 🧪 Biotechnology Industry
- Dominique Monnet CEO
5 rated
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
Financial statements — PDL BioPharma
The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
| 19 ← 15 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|
| Total Revenue |
|
55M | 200M | 320M | 240M | 590M |
| Cost Of Revenue |
|
54M | 48M | 31M | 4.1M | 0 |
| Gross Profit |
|
1.1M | 150M | 290M | 240M | 590M |
| Research and Development |
|
7.3M | 3M | 7.4M | 3.8M | 0 |
| Selling General and Admin |
|
54M | 63M | 63M | 40M | 36M |
| Operating Expense |
|
120M | 130M | 130M | 60M | 36M |
| Operating Income |
|
-67M | 68M | 190M | 180M | 550M |
| Other Income Expense Net |
|
0 | 0 | 0 | 0 | 0 |
| EBIT |
|
-30M | 68M | 190M | 180M | 550M |
| Interest Income |
|
11M | 12M | 20M | 18M | 27M |
| Pretax Income |
|
-74M | -56M | 180M | 110M | 530M |
| Income Tax |
|
-3M | 13M | 74M | 46M | 200M |
| Minority Interest |
|
-280K | 0 | -47K | 53K | 0 |
| Net Income |
|
-70M | -69M | 110M | 64M | 330M |
| Net Income Basic |
|
-70M | -69M | 110M | 64M | 330M |
| 19 ← 15 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|
| Current cash |
|
190M | 390M | 530M | 170M | 220M |
| Short term investments |
|
15M | 19M | 14M | 77M | 3M |
| Receivables |
|
66M | 85M | 85M | 150M | 58M |
| Inventory |
|
40M | 19M | 9.1M | 2.9M | 0 |
| Other current assets |
|
15M | 19M | 14M | 77M | 3M |
| Current assets |
|
310M | 520M | 640M | 400M | 280M |
| Long term investments |
|
400M | 450M | 600M | 820M | 730M |
| Property plant equipment |
|
5.5M | 7.4M | 7.2M | 38K | 31K |
| Goodwill |
|
0 | 0 | 0 | 0 | 0 |
| Intangible assets |
|
290M | 430M | 570M | 630M | 400M |
| Other assets |
|
25M | 9.8M | 28M | 170M | 320M |
| Total assets |
|
720M | 960M | 1.2B | 1.2B | 1B |
| Accounts payable |
|
17M | 13M | 20M | 7M | 390K |
| Current long term debt |
|
0 | 0 | 130M | 88M | 25M |
| Other current liabilities |
|
28M | 39M | 47M | 35M | 11M |
| Total current liabilities |
|
46M | 52M | 190M | 130M | 37M |
| Long term debt |
|
27M | 120M | 120M | 230M | 230M |
| Other liabilities |
|
49M | 43M | 86M | 97M | 51M |
| Minority Interest |
|
78K | 0 | 0 | 4.3M | 0 |
| Total Liabilities |
|
120M | 230M | 400M | 460M | 320M |
| Common stock |
|
-78M | -97M | -100M | -110M | -120M |
| Retained earning |
|
670M | 830M | 950M | 860M | 810M |
| Treasury stock |
|
0 | -2.1M | 0 | 0 | 0 |
| Capital surplus |
|
• | • | • | • | • |
| Shareholder equity |
|
590M | 730M | 850M | 750M | 700M |
| Net tangible assets |
|
300M | 300M | 280M | 120M | 300M |
| 19 ← 15 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|
| Net Income |
|
-70M | -69M | 110M | 64M | 330M |
| Depreciation |
|
6.3M | 16M | 25M | 12M | 0 |
| Changes in receivables |
|
-19M | -110K | -67M | 93M | 500K |
| Changes in inventories |
|
21M | 9.8M | 6.3M | 2.9M | 0 |
| Cash change |
|
-200M | -140M | 360M | -53M | -73M |
| Cash flow |
|
32M | 13M | 41M | 100M | 300M |
| Capital expenditures |
|
-760K | -4.5M | -1.3M | -25K | -9K |
| Investments |
|
• | • | • | • | • |
| Investing activity other |
|
• | • | • | • | • |
| Total investing cash flows |
|
22M | 57M | 460M | -140M | -80M |
| Dividends paid |
|
9K | • | • | • | • |
| Net borrowings |
|
-180M | -290M | -300M | 77M | 34M |
| Other financing cash flows |
|
• | • | • | • | • |
| Cash flow financing |
|
-190M | -180M | -120M | -29M | -290M |
| Exchange rate effect |
|
• | • | • | • | • |
Produces and markets biopharmaceutical products